This record is drawn from Quidel's Form 8-K press release exhibit dated December 23, 2021, corroborated by a May 6, 2022 Form 8-K/supplemental-disclosure filing by Ortho Clinical Diagnostics that explicitly references "Opinion of Perella Weinberg Partners LP, Arch's Financial Advisor" language adjacent to the deal's financial analyses (the supplemental filing confirms Perella Weinberg's continued role through the proxy process). At signing, the deal had unanimous board approval from both companies and was awaiting shareholder votes and regulatory clearance.
On the financial advisory side, Perella Weinberg Partners LP and Citi both advised Quidel, the acquirer, with the release stating "Quidel's financial advisors in connection with this acquisition are Perella Weinberg Partners LP and Citi, and its legal advisor is Gibson, Dunn & Crutcher LLP." J.P. Morgan Securities LLC served as Ortho's sole, exclusive financial advisor, per "Ortho's exclusive financial advisor is J.P. Morgan Securities LLC, and its legal advisor is Latham & Watkins LLP," making J.P. Morgan the only named lead advisor among the group given its exclusive mandate.
Legal counsel was split along the same lines: Gibson, Dunn & Crutcher LLP advised Quidel, while Latham & Watkins LLP advised Ortho.
Under the terms, Ortho shareholders were to receive $7.14 in cash plus 0.1055 shares of the combined company's stock for each Ortho share, leaving Ortho holders with roughly 38% of the combined company; Quidel also assumed Ortho's existing net debt of approximately $2.0 billion. The deal was expected to close in the first half of 2022, subject to shareholder and regulatory approvals. Not disclosed in the fetched documents is a final completion date (only "first half of 2022" is given), and the precise split between the cash and stock components of the aggregate $6.0 billion headline figure beyond the per-share cash/stock mix is not broken out as an aggregate dollar split.